 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 March 1997 | Volume 126 Issue 6 | Pages 468-479
Purpose: To evaluate the potential benefits, harms, and economic consequences of digital rectal examination and measurement of prostate-specific antigen (PSA) for the early detection of prostate cancer.
Data Sources: Relevant studies were identified from a MEDLINE search (1966 to 1995), reviews, bibliographies of retrieved articles, author files, and abstracts.
Study Selection: Probabilities for individual clinical outcomes were derived from various sources, including the largest screening study of community volunteers to date, analyses of Medicare claims, and recently published meta-analyses of the outcomes of alternative treatment strategies. Cost estimates were based on the 1992 Medicare fee schedule.
Data Extraction: A cost-effectiveness model for one-time digital rectal examination and PSA measurement was constructed to examine the possible outcomes.
Results: If a favorable set of assumptions is used, one-time digital rectal examination and PSA measurement may increase average life expectancy by approximately 2 weeks at a reasonable marginal cost for men who are between 50 and 69 years of age. Considerable iatrogenic illness would occur. If less favorable assumptions are used, the estimated net benefit would decrease and cost-effectiveness ratios would dramatically increase. Even if favorable assumptions are used, the model suggests that screening adds only a few days to the average life expectancy of men who are older than 69 years of age. If the assumptions are less favorable, older men are harmed.
Conclusions: The model suggests that screening may be reasonable in younger men if optimistic assumptions consistent with existing observational data are made. The lack of direct evidence showing a net benefit of screening for prostate cancer seems to mandate more clinician-patient discussion for this procedure than for many other routine tests.
Author and Article Information
From Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; Mount Sinai School of Medicine, New York, New York; and Health Outcomes Associates, Vancouver, Washington.
POSITION PAPER
CLINICAL GUIDELINES: PART II: Early Detection of Prostate Cancer: Part II
Estimating the Risks, Benefits, and Costs
Note: Much of the analytic work presented in this paper is that of the Patient Outcomes Research Team for Prostatic Diseases and was done under contract K3-0546.0 from the Office of Technology Assessment, Congress of the United States. The conclusions are solely those of the authors and do not represent the views of the Office of Technology Assessment, the Technology Assessment Board, or the United States Congress.
Grant Support: In part by grant HS-08397 from the Agency for Health Care Policy and Research (Patient Outcomes Research Team for Prostatic Diseases).
Requests for Reprints: Michael J. Barry, MD, Medical Practices Evaluation Center, Massachusetts General Hospital, 50 Staniford Street, Boston, MA 02114.
Current Author Addresses: Dr. Coley: Harvard University Health Services, 75 Mount Auburn Street, Cambridge, MA 02138.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  G. Wong, J. R. Chapman, and J. C. Craig Cancer Screening in Renal Transplant Recipients: What Is the Evidence? Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(Supplement_2): S87 - S100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ross, C. L. Kohler, D. M. Grimley, B. L. Green, and C. Anderson-Lewis Toward a Model of Prostate Cancer Information Seeking: Identifying Salient Behavioral and Normative Beliefs Among African American Men Health Educ Behav, June 1, 2007; 34(3): 422 - 440. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Losina, R. P. Walensky, A. Geller, F. C. Beddingfield III, L. L. Wolf, B. A. Gilchrest, and K. A. Freedberg Visual Screening for Malignant Melanoma: A Cost-effectiveness Analysis Arch Dermatol, January 1, 2007; 143(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lu-Yao, T. A. Stukel, and S.-L. Yao Prostate-Specific Antigen Screening in Elderly Men J Natl Cancer Inst, December 3, 2003; 95(23): 1792 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Fletcher Screening Sigmoidoscopy-- How Often and How Good? JAMA, July 2, 2003; 290(1): 106 - 108. [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Sorum, J. Shim, G. Chasseigne, S. Bonnin-Scaon, J. Cogneau, and E. Mullet Why do Primary Care Physicians in the United States and France Order Prostate-Specific Antigen Tests for Asymptomatic Patients? Med Decis Making, July 1, 2003; 23(4): 301 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 E. C. Y. Chan, S. W. Vernon, F. T. O'Donnell, C. Ahn, A. Greisinger, and D. W. Aga Informed Consent for Cancer Screening With Prostate-Specific Antigen: How Well Are Men Getting the Message? Am J Public Health, May 1, 2003; 93(5): 779 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Harris and K. N. Lohr Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, December 3, 2002; 137(11): 917 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Sox Disease Prevention Guidelines from the U.S. Preventive Services Task Force Ann Intern Med, January 15, 2002; 136(2): 155 - 156. [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Quinn, S. M. Henshall, A.-M. Haynes, P. C. Brenner, R. Kooner, D. Golovsky, J. Mathews, G. F. O'Neill, J. J. Turner, W. Delprado, et al. Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models J. Clin. Oncol., August 15, 2001; 19(16): 3692 - 3705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bosompra, T. Ashikaga, B. S. Flynn, J. K. Worden, and L. J. Solomon Psychosocial factors associated with the public's willingness to pay for genetic testing for cancer risk: a structural equations model Health Educ. Res., April 1, 2001; 16(2): 157 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Bayoumi, A. D. Brown, and A. M. Garber Cost-Effectiveness of Androgen Suppression Therapies in Advanced Prostate Cancer J Natl Cancer Inst, November 1, 2000; 92(21): 1731 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Jager and J. L. Severens To the Editor Med Decis Making, July 1, 2000; 20(3): 355 - 356. [PDF]
|
|
|
|
 |
|
 G. J. Jager, J. L. Severens, J. R. Thornbury, J. J. M. C. H. de la Rosette, S. H. J. Ruijs, and J. O. Barentsz Prostate Cancer Staging: Should MR Imaging Be Used?-A Decision Analytic Approach Radiology, May 1, 2000; 215(2): 445 - 451. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. A. Grover, L. Coupal, H. Zowall, R. Rajan, J. Trachtenberg, M. Elhilali, M. Chetner, and L. Goldenberg The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model Can. Med. Assoc. J., April 1, 2000; 162(7): 987 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Potosky, L. C. Harlan, J. L. Stanford, F. D. Gilliland, A. S. Hamilton, P. C. Albertsen, J. W. Eley, J. M. Liff, D. Deapen, R. A. Stephenson, et al. Prostate Cancer Practice Patterns and Quality of Life: the Prostate Cancer Outcomes Study J Natl Cancer Inst, October 20, 1999; 91(20): 1719 - 1724. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Volk, A. R. Cass, and S. J. Spann A Randomized Controlled Trial of Shared Decision Making for Prostate Cancer Screening Arch Fam Med, July 1, 1999; 8(4): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stern, D. Altkorn, and W. Levinson Detection of Prostate and Colon Cancer JAMA, July 8, 1998; 280(2): 117 - 118. [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Collins, F. J. Fowler Jr., R. G. Roberts, J. E. Oesterling, G. J. Annas, and M. J. Barry Medical Malpractice Implications of PSA Testing for Early Detection of Prostate Cancer J. Law Med. Ethics, December 1, 1997; 25(4): 234 - 242. [PDF]
|
|
Article
